blocked randomisation method (Amgen)
90
Structured Review
Amgen
blocked randomisation method
Blocked Randomisation Method, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocked+randomisation+method/randomisation+lists/pmc10445271-186-25-20
Average 90 stars, based on 1 article reviews
Blocked Randomisation Method, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/blocked+randomisation+method/randomisation+lists/pmc10445271-186-25-20
Average 90 stars, based on 1 article reviews
blocked randomisation method - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "TPO receptor agonist for chronic idiopathic thrombocytopenic purpura"
Article Title: TPO receptor agonist for chronic idiopathic thrombocytopenic purpura
Journal: The Cochrane Database of Systematic Reviews
doi: 10.1002/14651858.CD008235.pub2
Figure Legend Snippet: Kuter 2008a
Techniques Used: Sequencing, Selection, Generated, Sterility, Injection
Figure Legend Snippet: Kuter 2008b
Techniques Used: Sequencing, Selection, Generated, Sterility, Injection
Related Articles
Selection:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The randomisation lists will be generated by Amgen using a permuted block design within each strata... .. Comment: probably done Allocation concealment (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): ”Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.“ Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 30): Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): “Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.” Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Generated:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The randomisation lists will be generated by Amgen using a permuted block design within each strata... .. Comment: probably done Allocation concealment (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): ”Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.“ Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. The Article Title: Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial Article Snippet: Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK (Prof R Coleman FRCP); Massachusetts General Hospital, Boston, MA, USA (Prof D M Finkelstein PhD); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil (C Barrios MD); Instituto de Investigacion Sanitaria Gregorio Marañon, Ciberonc, Geicam, Universidad Complutense, Madrid, Spain (Prof M Martin MD); Aichi Cancer Center Hospital, Nayoya, Japan (H Iwata MD); Hospital Pérola Byington and Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil (R Hegg MD); UCLA School of Medicine, Los Angeles, CA, USA (Prof J Glaspy MD); Hospital Universitario Virgen del Rocio, Sevilla, Spain (A M Periañez PhD); Cross Cancer Institute, Edmonton, AB, Canada (Prof K Tonkin MD); Oncology Center, AZ Nikolass, Sint-Niklaas, Belgium (I Deleu MD); Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea (Prof J Sohn MD); All-Ireland Co-Operative Oncology Research Group, Dublin, Ireland (J Crown BCh); Institut Gustave Roussy, Villejuif, France (S Delaloge MD); Amgen Inc, Thousand Oaks, CA, USA (T Dai PhD, Y Zhou PhD, D Jandial MD); and Breast Cancer Research Centre Western Australia and School of Medicine, Curtin University, Perth, WA, Australia (Prof A Chan FRACP) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial Article Title: Psoriasis and sleep disorders: A systematic review. Article Snippet: .. Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 30): Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): “Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.” Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Angiogenesis inhibitors for the treatment of epithelial ovarian cancer Article Snippet: Cochrane Library Trusted evidence.. Informed decisions.. Better health. Blocking Assay:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The randomisation lists will be generated by Amgen using a permuted block design within each strata... .. Comment: probably done Allocation concealment (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): ”Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.“ Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): “Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.” Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Sequencing:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): ”Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.“ Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 30): Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis Article Snippet: ... and Amgen conducted the data analyses. .. All the authors interpreted the data” Declarations of interest (p 1327): “Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.” Dr. Lebwohl reports grant support from Amgen, AbbVie, Janssen Biotech, UCB Pharma, Pfizer, Celgene, Eli Lilly, and Novartis outside the submitted work Risk of bias Bias Authors’ judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (protocol): “The Article Title: Angiogenesis inhibitors for the treatment of epithelial ovarian cancer Article Snippet: Cochrane Library Trusted evidence.. Informed decisions.. Better health. |